Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results
Siamak Daneshmand et al. J Urol. 2004 Dec.
Abstract
Purpose: We determined the prognostic factors that affect recurrence and survival in patients with lymph node positive prostate cancer.
Materials and methods: Between 1972 and 1999, 1,936 patients underwent radical retropubic prostatectomy and pelvic lymph node dissection for clinically organ confined prostate cancer. A total of 235 patients (12.1%) were found to have disease metastatic to the lymph nodes (stage D1). Of the patients 69% received no adjuvant treatment. We reviewed the tumor stage (TNM), Gleason score, number and percent of involved lymph nodes (lymph node density), preoperative prostate specific antigen when available and adjuvant treatment. Overall survival and recurrence-free survival were estimated using Kaplan-Meier plots.
Results: Followup was 1 to 24 years (median 11.4). Overall median survival was 15 years. Overall clinical recurrence-free survival at 5, 10 and 15 years was 80%, 65% and 58%, respectively. Patients who had 1 or 2 positive lymph nodes had a clinical recurrence-free survival of 70% and 73% at 10 years, respectively, vs 49% in those who had 5 or more involved lymph nodes (p = 0.0031). When stratified by lymph node density, patients with a lymph node density of 20% or greater were at higher risk for clinical recurrence compared to those with a density of less than 20% (relative risk = 2.32, p <0.0001). On stratified log rank test only prostate cancer T stage, and the number and percent of positive lymph nodes correlated with recurrence-free and overall survival.
Conclusions: Local tumor bulk and the number/percent of involved lymph nodes significantly affect disease progression and the survival rate. Radical prostatectomy may offer long-term survival in patients who have limited tumor bulk and nodal involvement.
Comment in
Re: Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results.
Maffezzini M. Maffezzini M. J Urol. 2005 Sep;174(3):1151-2; author reply 1152. doi: 10.1097/01.ju.0000169157.74608.3a. J Urol. 2005. PMID: 16094087 No abstract available.
Similar articles
Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML. Boorjian SA, et al. J Urol. 2007 Sep;178(3 Pt 1):864-70; discussion 870-1. doi: 10.1016/j.juro.2007.05.048. Epub 2007 Jul 16. J Urol. 2007. PMID: 17631342
-
Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
Bader P, Burkhard FC, Markwalder R, Studer UE. Bader P, et al. J Urol. 2003 Mar;169(3):849-54. doi: 10.1097/01.ju.0000049032.38743.c7. J Urol. 2003. PMID: 12576797
Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy.
von Bodman C, Godoy G, Chade DC, Cronin A, Tafe LJ, Fine SW, Laudone V, Scardino PT, Eastham JA. von Bodman C, et al. J Urol. 2010 Jul;184(1):143-8. doi: 10.1016/j.juro.2010.03.039. Epub 2010 May 15. J Urol. 2010. PMID: 20478587 Free PMC article.
Long-term oncological outcomes after laparoscopic radical prostatectomy.
Hruza M, Bermejo JL, Flinspach B, Schulze M, Teber D, Rumpelt HJ, Rassweiler JJ. Hruza M, et al. BJU Int. 2013 Feb;111(2):271-80. doi: 10.1111/j.1464-410X.2012.11317.x. Epub 2012 Jul 3. BJU Int. 2013. PMID: 22757970 Review.
The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature.
Gakis G, Boorjian SA, Briganti A, Joniau S, Karazanashvili G, Karnes RJ, Mattei A, Shariat SF, Stenzl A, Wirth M, Stief CG. Gakis G, et al. Eur Urol. 2014 Aug;66(2):191-9. doi: 10.1016/j.eururo.2013.05.033. Epub 2013 May 22. Eur Urol. 2014. PMID: 23735200 Review.
Cited by
Patients with Positive Lymph Nodes after Radical Prostatectomy and Pelvic Lymphadenectomy-Do We Know the Proper Way of Management?
Małkiewicz B, Knura M, Łątkowska M, Kobylański M, Nagi K, Janczak D, Chorbińska J, Krajewski W, Karwacki J, Szydełko T. Małkiewicz B, et al. Cancers (Basel). 2022 May 8;14(9):2326. doi: 10.3390/cancers14092326. Cancers (Basel). 2022. PMID: 35565455 Free PMC article. Review.
99mTc-PSMA targeted robot-assisted radioguided surgery during radical prostatectomy and extended lymph node dissection of prostate cancer patients.
Yılmaz B, Şahin S, Ergül N, Çolakoğlu Y, Baytekin HF, Sökmen D, Tuğcu V, Taşçı Aİ, Çermik TF. Yılmaz B, et al. Ann Nucl Med. 2022 Jul;36(7):597-609. doi: 10.1007/s12149-022-01741-9. Epub 2022 Apr 15. Ann Nucl Med. 2022. PMID: 35426599
Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death.
Tilki D, Chen MH, Wu J, Huland H, Graefen M, D'Amico AV. Tilki D, et al. J Clin Oncol. 2022 Jul 10;40(20):2186-2192. doi: 10.1200/JCO.21.02800. Epub 2022 Mar 15. J Clin Oncol. 2022. PMID: 35290082 Free PMC article.
Radiomics for Identification and Prediction in Metastatic Prostate Cancer: A Review of Studies.
Kendrick J, Francis R, Hassan GM, Rowshanfarzad P, Jeraj R, Kasisi C, Rusanov B, Ebert M. Kendrick J, et al. Front Oncol. 2021 Nov 1;11:771787. doi: 10.3389/fonc.2021.771787. eCollection 2021. Front Oncol. 2021. PMID: 34790581 Free PMC article. Review.
Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer.
Malaspina S, Anttinen M, Taimen P, Jambor I, Sandell M, Rinta-Kiikka I, Kajander S, Schildt J, Saukko E, Noponen T, Saunavaara J, Dean PB, Sequeiros RB, Aronen HJ, Kemppainen J, Seppänen M, Boström PJ, Ettala O. Malaspina S, et al. Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2951-2959. doi: 10.1007/s00259-021-05296-1. Epub 2021 Mar 13. Eur J Nucl Med Mol Imaging. 2021. PMID: 33715033 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
- Atypon
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- Genetic Alliance
- MedlinePlus Health Information